KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings: 2009-2025

Historic Retained Earnings for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to -$7.2 billion.

  • Alnylam Pharmaceuticals' Retained Earnings rose 0.60% to -$7.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 billion, marking a year-over-year increase of 0.60%. This contributed to the annual value of -$7.3 billion for FY2024, which is 3.97% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Retained Earnings stood at -$7.2 billion for Q3 2025, which was up 3.39% from -$7.4 billion recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Retained Earnings peaked at -$4.8 billion during Q1 2021, and registered a low of -$7.4 billion during Q2 2025.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Retained Earnings value was -$7.1 billion (recorded in 2024), while the average stood at -$7.1 billion.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Retained Earnings decreased by 22.82% in 2022, and later rose by 0.60% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Retained Earnings (Quarterly) stood at -$5.4 billion in 2021, then fell by 20.80% to -$6.6 billion in 2022, then dropped by 6.70% to -$7.0 billion in 2023, then dropped by 3.97% to -$7.3 billion in 2024, then rose by 0.60% to -$7.2 billion in 2025.
  • Its last three reported values are -$7.2 billion in Q3 2025, -$7.4 billion for Q2 2025, and -$7.3 billion during Q1 2025.